Drug Database
Back to search

Netherlands· NL-3c536ab4611c

Esketamine 5 mg/ml Focus, oplossing voor injectie / infusie

A esketamine product containing esketaminehydrochloride, registered in Netherlands by Focus Care Pharmaceuticals B.V.. The same ATC class is registered in 8 of our 19 countries.

ATC N01AX14

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEsketamine 5 mg/ml Focus, oplossing v…ATCN01AX14REGISTER NO.NL-3c536ab4611cPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about esketaminehydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Esketamine is registered in 8 of 19 countries.

Countries holding a registration under ATC N01AX14 (esketamine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search esketamine products by name

Esketamine · ATC N01AX14

8 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ESKETAMINEHYDROCHLORIDE
Manufacturer
Focus Care Pharmaceuticals B.V.
Country
Netherlands (NL)
ATC code
N01AX14
ATC class
Esketamine
Defined daily dose
0.125 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    126328

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

91 interactions on record for esketamine.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check esketamine against other medicinesHow interaction checks work

Esketamine · interactions on record

91 records

  • 7 severe
  • 84 moderate

Most severe, free to view

  • PhentermineA08AA01severe
  • FenfluramineA08AA02severe
  • MazindolA08AA05severe
  • FenfluramineN03AX26severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Esketamine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All esketamine products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Escetex, Eskelan
  • Belgium · Esketamine Kalceks, Vesierra
  • Germany · Esketamin, Esketamin Inresa
  • Denmark · Esketamine Orifarm, S-Ketamin Pfizer
  • Estonia · Esketex
  • Finland · Esketamine Kalceks, Esketamine Orifarm
  • France · Eskesia, Esketamine Renaudin
  • United Kingdom (Northern Ireland) · Esketamine Idd, Esketamine Kalceks
  • Croatia · Esgamda
  • Iceland · S-Ketamin Pfizer, Spravato
  • Liechtenstein · Spravato
  • Luxembourg · Vesierra
  • Latvia · Esketamine Kalceks
  • Norway · Ketanest, Sinmelan
  • Sweden · Esketamine Kalceks, Esketamine Orifarm
  • Slovenia · Esketamin Kalceks, Sinmelan

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/580b9a03-5eb7-4b19-841b-3de9fd2b726a
GET /v1/drugs/580b9a03-5eb7-4b19-841b-3de9fd2b726a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie of infusie",
  "route": "Intraveneus gebruik, Intramusculair gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h126328_smpc.pdf",
  "strength": null,
  "atc_label": "Esketamine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg126328",
  "excipients": [
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "ESKETAMINEHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h126328.pdf",
  "authorised_at": "2024/07/18",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "126328",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about esketamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console